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Biological differences between males and females change the course of different
diseases and affect therapeutic measures’ responses. Heart failure is not an exception
to these differences. Women account for a minority of patients on the waiting list for
heart transplantation or other advanced heart failure therapies. The reason for this under-
representation is unknown. Men have a worse cardiovascular risk profile and suffer
more often from ischemic heart disease. Conversely, transplanted women are younger
and more frequently have non-ischemic cardiac disorders. Women’s poorer survival on
the waiting list for heart transplantation has been previously described, but this trend
has been corrected in recent years. The use of ventricular assist devices in women is
progressively increasing, with comparable results than in men. The indication rate for a
heart transplant in women (number of women on the waiting list for millions of habitants)
has remained unchanged over the past 25 years. Long-term results of heart transplants
are equal for both men and women. We have analyzed the data of a national registry of
heart transplant patients to look for possible future directions for a more in-depth study
of sex differences in this area. We have analyzed 1-year outcomes of heart transplant
recipients. We found similar results in men and women and no sex-related interactions
with any of the factors related to survival or differences in death causes between men
and women. We should keep trying to approach sex differences in prospective studies to
confirm if they deserve a different approach, which is not supported by current evidence.
Keywords: gender, female, heart transplantation, outcome, women, advanced heart failure, ventricular assist
device
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INTRODUCTION
There is a growing interest in sex-related differences in several
clinical scenarios. Men and women differ in body composition
and physiology; they present differences in pharmacokinetics
and pharmacodynamics; and they may also respond differently
to cardiovascular drugs. Women are underrepresented in most
clinical trials, and real-life data have shown that they are less often
treated with evidence-based therapies and experience adverse
drug reactions more often (1). The reason for these differences
between men and women is beyond the scope of the present
study. Still, a better knowledge of these sex-related differences
may be helpful to improve patient care.
Most heart failure (HF) patients are female. Women have
a different clinical profile than men (2); they develop end-
stage HF at an older age, have a higher prevalence of HF with
preserved ejection fraction and a lower prevalence of ischemic
heart disease (IHD) (3–5). HF prognosis seems to be better in
women with a lower rate of premature death than men (4).
Moreover, in HF with reduced ejection fraction, women seem
to have a better response to treatment, with a more favorable
reverse remodeling regardless of the cause and severity of the left
ventricle systolic dysfunction (5). In the field of advanced HF, the
underrepresentation of women among heart transplant (HT) or
ventricular assist devices (VAD) recipients has been attributed to
selection and referral bias and potentially poorer outcomes for
these therapies. However, whether the described better outcomes
in women with HF may also explain this under-representation in
advanced heart failure stages has not been explored.
The majority of the studies in the field of heart transplantation
(HT) are focused on donor-recipient mismatch (6–8). However,
sex-related differences in patients on the waiting list for an HT or
ventricular assist device and long term survival after an HT have
been addressed recently. We aim to review those topics and look
for sex-related differences in 1-year outcomes after an HT in an
extensive nationwide registry to elucidate possible gaps that may
need further investigation in the future.
MATERIALS AND METHODS
Data Source
The Spanish Heart Transplant Registry is a prospective database
promoted by the Heart Failure Working Group of the Spanish
Society of Cardiology, containing detailed clinical information
about all HT procedures performed in our country from 1984 to
the present. The registry is updated yearly with data supplied by
all transplant centers in the country (9). The Ethics Committees
of all participating centers have approved the Spanish Heart
Transplantation Registry for investigational purposes.
For the present study, we included all patients aged ≥18
years who underwent an HT in Spain from January 1, 2005
to December 31, 2019. Vital status at the end of follow-
up and cause of death (when applicable) was known for all
participants. The cause of death was locally adjudicated in each
Abbreviations: DCM, Dilated cardiomyopathy; HF, Heart Failure; HT, Heart
transplant; IHD, ischemic heart disease; VAD, Ventricular assist device.
participating center. We excluded recipients of a second HT and
multiorgan recipients.
Missing Data
Missing data (Supplementary Table 1) were handled by multiple
imputations using the wholly conditional specification method,
generating 10 imputed datasets using all applicable adjustment
variables and the outcome variable as predictors. The average of
the 10 imputed data sets was used for analysis. For imputation,
categorical and continuous variables were modeled using logistic
regression and linear regression, respectively.
Statistical Analysis
Quantitative variables were summarized as median (interquartile
range), and the Mann-Whitney U-test assessed between-
sex differences. Categorical variables were summarized as
percentages, with Chi-squared or Fisher’s exact tests, as
appropriate, for between-sex comparisons.
The primary outcome was 1-year all-cause mortality
or re-transplantation. The associations between baseline
population characteristics and outcome were fitted by the
use of Cox proportional hazards regression. Multivariable
adjustment included the recipient’s sex and those variables
with a significance level <0.10 in the univariable analysis. To
further explore possible differences between men and women,
additional multivariable models were considered to include the
interaction between the recipient sex and each variable that
reached statistical significance in the final multivariable analysis.
All statistical tests were 2-sided, and a p-value <0.05 was
considered significant. All analyses were performed using the
SPSS 25.0 (SPSS Inc., Chicago, IL).
RESULTS
A total of 3,616 HT procedures were performed in 16 HT
centers during the study period. We identified 869 female
recipients (24%). Sex-stratified baseline characteristics of the
study population are shown in Table 1.
Women were significantly younger, and had a lower body
mass index and predicted heart mass than men. They also
presented with history of neoplastic disease more often.
Men had a poorer cardiovascular risk profile assessed as
a higher prevalence of hypertension and diabetes, and triple
the prevalence of peripheral artery disease. They also had two
times the prevalence of chronic obstructive pulmonary disease.
Men had undergone previous cardiac surgery more frequently
than women.
HT indication was mainly due to IHD in men. Conversely,
in women, HT’s leading cause was dilated cardiomyopathy
(DCM), followed by other etiologies (valvular heart disease,
congenital heart disease, hypertrophic cardiomyopathy,
restrictive cardiomyopathy, and myocarditis).
Urgent HT and mechanical circulatory support (VAD and
intra-aortic balloon pump) were more frequent in men.
Abnormal bilirubin levels and active infection at the moment of
HT were also more frequent in men.
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TABLE 1 | Characteristics of the study cohort stratified by gender.
Female Male P-value
(n = 869) (n = 2,747)
Recipient





Predicted heart mass (g) 126.8 (118.1, 138.2) 176.0 (164.5, 189.2) <0.001
Body mass index (Kg/m2) 24.0 (21.3, 27.6) 25.5 (23.4, 28.2) <0.001
Diabetes (%) 12.1 23.3 <0.001
Hypertension (%) 23.2 38.9 <0.001
COPD (%) 6.1 12.2 < 0.001
Peripheral vascular disease (%) 2.6 7.8 <0.001
Pretransplant malignancy (%) 8.5 4.1 <0.001
GFR (ml/min/1.73 m2) 71.1 (51.4, 95.0) 71.3 (52.8, 94.5) 0.64
GFR < 45 mL/min/1.73 m2 17.6 15.0 0.08
CMV serology positive 82.3 80.0 0.15
Bilirubin >2 mg/dL 15.3 18.9 0.02
Pulmonary vascular resistance (WU) 2.0 (1.3, 2.9) 2.0 (1.3, 2.8) 0.42
Pre-transplant cardiac surgery (%) 25.3 29.2 0.03
Pre-transplant infection (%) 10.4 14.8 0.001
Pre-transplant mechanical ventilation (%) 15.5 14.4 0.44





Recipient location (%) 0.08
Home 56.0 52.5
Hospital ward 11.4 10.7
Intensive care unit 32.6 36.8
Surgical procedure
Urgent transplant (%) 33.8 37.9 0.03
Cold ischemic time (min) 210.0 (153.3, 240.0) 205.0 (155.0, 245.0) 0.94






Age (years) 45.0 (34.0, 53.0) 44.0 (32.0, 52.0) 0.11
Gender (female) 57.3 28.7 <0.001
Predicted heart mass (g) 139.3 (129.0, 152.0) 184.0 (169.5, 199.0) <0.001
Body mass index (Kg/m2) 24.4 (22.5, 26.7) 26.0 (24.0, 28.4) <0.001
CMV serology positive 74.4 72.3 0.25





Donor/recipient gender mismatch (%) 42.7 28.7 <0.001
(Continued)
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TABLE 1 | Continued
Female Male P-value
(n = 869) (n = 2,747)
Donor/recipient predicted heart mass ratio 1.09 (1.00, 1.12) 1.03 (0.96, 1.13) <0.001
Donor/recipient CMV serology mismatch (%) 34.9 36.2 0.81
Donor/recipient BMI ratio 1.00 (0.89, 1.16) 1.01 (0.91, 1.14) 0.31
COPD, Chronic Obstructive Pulmonary Disease; GFR, Glomerular Filtration Rate; CMV, cytomegalovirus; WU, wood units; IABP, Intraaortic balloon pump; ECMO, extracorporeal
membrane oxygenator; VAD, ventricular assist device; CVD, cerebrovascular disease.
Although women received grafts from female donors who had
a lower body mass index and predicted heart mass more often,
donor/recipient sex mismatch was more frequent. Consequently,
donor/recipient predicted heart mass ratio was higher.
Median follow-up was 1.01 years (interquartile range 0.71–
1.01). Results of the univariate and multivariate Cox regression
analysis are summarized in Table 2. Variables related to impaired
survival included recipient age, higher body mass index, diabetes
mellitus, bilirubin of >2 mg/dl, pre-HT infection, previous
cardiac surgery, need for mechanical ventilation at the moment
of HT, mechanical circulatory support at the time of HT, recipient
location in the Intensive Care Unit, urgent transplant, cold
ischemic time, female donor and donor/recipient sex mismatch,
and donor/recipient body mass index ratio. Higher glomerular
filtration rate, bicaval surgical technique, and HT in the recent
period (2015–2019) were related to a better outcome. After
multivariate analysis, body mass index and diabetes of the
recipient lost statistical significance as did any type of mechanical
circulatory support at the time of HT, recipient location at the
time of HT, urgent status, female donor, and donor-recipient
body mass index.
In the final model, variables independently related to reduced
survival were recipient age, history of previous cardiac surgery,
bilirubin of >2 mg/dl, pre-HT infection, need for mechanical
ventilation at the moment of HT, cold ischemic time, and
donor/recipient sex mismatch. Higher glomerular filtration rate,
bicaval surgical technique, and HT in the recent period (2015–
2019) were independently associated with a better prognosis.
Women and men had a similar 1-year survival (women 76.4
vs. 78.6% men p = 0.34) by adjusted Kaplan-Meier analysis
(Figure 1). We did not find any differences in the cause of death
between men and women (Figure 2).
We did not find any interaction between sex and variables
independently related to survival in the multivariate analysis
(Table 3).
DISCUSSION
Advanced heart failure affects 1–10% of the overall HF
population and implies a severe decline in patients’ quality of
life and survival. The Heart Failure Association of the European
Society of Cardiology has recently updated diagnostic criteria. It
focuses on patient referral to advanced HF centers and a proper
transition of patients to palliative care (10). Although there are
interesting HF registries to gather information about HF patients’
clinical parameters and characteristics and their therapies, the
advanced heart failure population is somehow challenging to
study and scarcely described in the literature. Gender differences
in HF patients have been previously described, but their clinical
implications remain unclear. A better knowledge of the sex-
related differences appears as a potential field of improvement
in the diagnosis, treatment, and likely prognosis of HF patients.
The more significant publications addressing sex differences
in advanced HF patients (waiting-list, HT, and VAD) are
summarized in Table 4.
Previous studies with a small sample of patients showed
a worse survival rate for women on the waiting list for HT
(19). Several analyses of the Scientific Registry of Transplant
Recipients of the United States of America have assessed the same
topic. Hsich et al. in 2014 analyzed sex differences in patients
listed for HT in 10 years (2000–2010) stratified by severity of
illness (1A, high risk; 1B, intermediate risk; and 2, low-risk
ambulatory patients) and adjusted by baseline characteristics.
Women accounted for 25% of the study population, and they
had a higher mortality rate than men in urgent status (1A) but
a lower mortality rate than men in an elective ambulatory setting
(status 2). No differences were observed in the intermediate-risk
status 1B (11). Women were younger and had a non-ischemic
cardiomyopathymore often, andmen had a worse cardiovascular
risk profile, and IHD was the leading cause for HF. The same
authors tried to confirm these sex differences in a more recent
period (2004–2015) and attempted to identify factors associated
with waiting-list mortality and transplantation timing. Although
similar differences in mortality were observed between 2004 and
2008 (higher mortality in woman in status 1A and 1B and lower
in status 2), in the most recent years, some of them were solved,
and women had a similar survival in urgent status (1A) and
elective status (2). They also identified many sex interactions
for death and HT that varied with prioritization on the waiting
list that should be addressed as a new field to understand these
differences between men and women (12). Improvements in the
risk of death or deterioration in women waiting for HT have also
been observed in other studies (20).
There is also available information about sex-related
differences in VAD therapy. As expected, baseline characteristics
and underlying comorbidities and etiologies differed between
men and women as it has been described for studies of patients
on the HT waiting list. An analysis of the European Registry
for Patients with Mechanical Circulatory Support showed that
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TABLE 2 | Uni- and multivariate Cox regression analysis of 1-y survival.
Univariate Multivariate
HR CI (95%) P-value HR CI (95%) P-value
Recipient
Female gender 1.11 0.94–1.30 0.21 1.15 0.97–1.36 0.10
Age (years) 1.01 1.01–1.02 <0.001 1.01 1.00–1.02 0.005
Predicted heart mass (g) 1.00 1.00–1.00 0.59
Body mass index (Kg/m2) 1.02 1.00–1.04 0.02 1.01 0.97–1.03 0.68
Etiology
Dilated 1
Ischemic 1.11 0.94–1.30 0.22
Other 1.16 0.97–1.40 0.11
Diabetes 1.18 1.00–1.40 0.05 1.11 0.93–1.33 0.23
Hypertension 1.13 0.98–1.32 0.10
COPD 1.09 0.87–1.36 0.48
PVD 1.20 0.92–1.56 0.18
GFR (mL/min/1.73 m2 ) 0.99 0.99–0.99 <0.001 0.99 0.99–1.00 <0.001
CMV serology positive 1.10 0.92–1.33 0.29
Bilirubin >2 mg/dL 1.49 1.25–1.78 <0.001 1.35 1.13–1.61 0.001
PVR (Wood U.) 1.05 1.00–1.11 0.08 1.02 0.97–1.08 0.42
Pre-transplant infection 1.60 1.34–1.92 <0.001 1.34 1.10–1.63 0.004
Pre-transplant cardiac surgery 1.32 1.14–1.53 <0.001 1.22 1.04–1.43 0.02
Mechanical ventilation 2.00 1.70–2.37 <0.001 1.64 1.32–2.05 <0.001
Pre-transplant circulatory support
None 1 1
IABP 1.45 1.18–1.77 <0.001 1.10 0.88–1.37 0.41
ECMO 1.69 1.34–2.15 <0.001 1.20 0.89–1.63 0.23
VAD 1.39 1.14–1.71 0.001 1.21 0.94–1.57 0.15
Recipient locationa
Home 1
Hospital ward 1.15 0.90–1.46 0.27
Intensive care unit 1.57 1.35–1.82 <0.001
Pre-transplant malignancy (%) 1.19 0.89–1.61 0.24
Surgical procedure
Urgent transplant 1.51 1.31–1.74 <0.001
Cold ischemic time (min) 1.00 1.00–1.00 <0.001 1.00 1.00–1.00 <0.001
Surgical technique (bicaval) (%) 0.78 0.68–0.90 0.001 0.85 0.73–0.99 0.03
Transplant era
2005–2009 1 1
2010–2014 0.90 0.76–1.07 0.24 0.91 0.77–1.09 0.30
2015–2019 0.72 0.61–0.86 <0.001 0.70 0.58–0.85 <0.001
Donor
Age (years) 1.00 1.00–1.01 0.22
Gender femalea 1.20 1.07–1.34 0.001
Predicted heart mass (g) 1.00 1.00–1.00 0.33
Body mass index (Kg/m2) 0.99 0.98–1.01 0.50
Cause of death
Trauma 1
CVD 0.95 0.81–1.13 0.56
Other 1.00 0.83–1.21 0.99
CMV serology positive 0.88 0.75–1.04 0.12
Donor/recipient interaction
(Continued)
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TABLE 2 | Continued
Univariate Multivariate
HR CI (95%) P-value HR CI (95%) P-value
Donor/recipient gender mismatch 1.16 1.00–1.34 0.049 1.22 1.05–1.42 0.01
Recipient/Donor CMV mismatch
No 1
Donor (−)/recipient (+) 1.14 0.96–1.37 0.14
Donor (+)/recipient (−) 0.91 0.73–1.15 0.43
Donor/recipient predicted heart mass ratio 0.92 0.55–1.54 0.75
Donor/recipient body mass index ratio 0.65 0.45–0.95 0.02 0.80 0.50–1.28 0.35
HR, Hazard ratio; CI, Confidence interval; COPD, Chronic obstructive pulmonary disease; CVD, cerebrovascular disease; ECMO, extracorporeal membrane oxygenator; GFR, glomerular
filtration rate; IABP, intra-aortic balloon pump; PVD, peripheral vascular disease; PVR, pulmonary vascular resistance; VAD, ventricular assist device.
aUrgent transplant, recipient location, and donor sex were not included in the multivariate model due to collinearity with Pre-transplant Circulatory Support and recipient and donor sex.
FIGURE 1 | Adjusted 1-year survival curves according to recipient sex.
only 15% of patients receiving a VAD were women. HT rates
were similar for men and women. However, women were at a
more advanced stage at the moment of implantation, presented
a higher rate of significant bleeding, arrhythmias, and right
ventricular failure, and had a worse prognosis than men (13).
Two studies in the United States of America also showed a
lower use of VAD in women, although slightly higher than in
the European Registry (21–23%). This higher percentage of
women undergoing a VAD implantation might be explained
by the inclusion of patients listed in a more recent time-lapse.
Increasing use of VAD therapy in women throughout the
observation period is described. Both American registries
represent conflicting results on survival. The former is focused
on in-hospital survival and showed similar survival for men
and women (15). The latter evaluated more extended follow-up
periods and described lower HT rates and a lower survival in
women (14). In both registries, women presented with a more
severe HF, but a similar adverse event rate. Those differences
in outcomes may reflect different follow-up times and, thus,
different rates of adverse events in men and women after
perioperative period.
Several factors might play a role in sex-related differences
in HT outcomes: the higher frequency of anti-HLA antibodies
detection in women, differences in predicted heart mass as a
critical factor in donor-recipient matching, and variability in
clinical presentation men and women (21, 22). The New Heart
study was the first one to address this topic. They found a similar
survival for HT in women, who represented 28% of the analyzed
population. Conversely, women were younger and developed
graft rejection and needed hospitalization more often than men
(16). An analysis of the International Society of Heart and Lung
Transplantation Registry, in which 23.7% of included patients
were women, also showed similar survival rates after adjusting by
recipient and donor risk scores but suggested a higher mortality
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FIGURE 2 | Causes of death segregated by sex. Data are expressed as count (percentage in the y-axis). Chi-square = 6.075; P = 0.41.
TABLE 3 | Analysis of interactions between recipient gender and significant variables in multivariate analysis.
Variable Recipient female gender Interaction
recipient sex * variable
HR CI (95%) P-value HR CI (95%) P-value
Recipient age 0.83 0.36–1.90 0.66 1.01 0.99–1.02 0.46
GFR (mL/min/1.73 m2 ) 1.01 0.64–1.60 0.95 1.00 0.99–1.01 0.64
Bilirubin >2 mg/dL 1.08 0.89–1.30 0.43 1.21 0.81–1.79 0.35
Pre-transplant infection 1.07 0.89–1.28 0.49 1.34 0.89–2.04 0.17
Pre-transplant cardiac surgery 1.08 0.88–1.31 0.47 1.14 0.81–1.61 0.46
Mechanical ventilation 1.11 0.92–1.34 0.30 1.06 0.73–1.54 0.76
Bicaval surgical technique 1.22 0.95–1.55 0.12 0.87 0.62–1.20 0.39
Cold ischemic time 0.81 0.46–1.44 0.47 1.00 1.00–1.00 0.24
Transplant era 1.04 0.79–1.37 0.76
2010–2014 1.20 0.81–1.77 0.37
2015–2019 1.05 0.70–1.56 0.81
Donor/Recipient gender mismatch 1.11 0.89–1.38 0.35 1.03 0.74–1.43 0.88
GFR, glomerular filtration rate.
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TABLE 4 | Summary of recent publications addressing gender differences in patients on the waiting for a heart transplant, receiving a long term ventricular assist device,
or heart transplant recipients.
Publication Population Period Analysis Conclusions





Women higher risk in urgent status
Similar results in intermediate status in men and women
Men higher risk in elective status
Hsich et al. (12) 33069 PWL
25% women
(SRTR)
2004–2015 3 year survival
Random survival forest
Higher risk in urgent and intermediate status in women,
similar in recent period
Higher risk in elective status in men
Multiple interactions between sex in different status
Magnussen et al. (13) 966 VAD (75% BTT)
15% women
(EUROMACS)
2011–2014 1–2-year survival Similar HT rates
Women worse survival
Women sicker at implant
Women higher major bleeding, arrhythmias, and RV failure





Increase in VAD use among decade (lower in women)
Women sicker at implant, similar complications
Women lower HT rate and survival







VAD in females have doubled lately
Hickey et al. (16) 345 HT
28% women
NEW HEART study
2011–2015 1-year survival Similar survival
Women younger
Women more rejection episodes and hospitalizations




Adjusted IMPACT / DRI
Long-term survival
Similar survival
Lowest survival in undersized donors
Women higher mortality in regular sized donors







Similar HT pmh in women among 25 years (lower in men)
Women died due to rejection and primary graft failure
Men died due to malignancies
Current series 3616 HT
24% women
(SHTR)
2005–2019 1-year survival Similar survival
PWL, Patients on the waiting list; SRTR, USA Scientific Registry of Transplant Recipients; VAD, long term ventricular assist device; BTT, bridge to transplantation; EUROMACS, European
Registry for Patients with Mechanical Circulatory Support; HT, Heart transplant; RV, right ventricle; UNOS, United Network for Organ Sharing; NIS, USA National Inpatient Database;
ISHLTR, International Society of Heart and Lung Transplantation Registry; IMPACT, Index for Mortality Prediction After Cardiac Transplantation score; DRI, Donor Risk Index; SHTR,
Spanish Heart Transplant Registry; Pmh, per million habitants.
rate to women who received a graft of a regular-sized donor
(17). Our previous work analyzing the Spanish Heart Transplant
Registry results over the last 25 years showed a similar survival
and similar HT rate in women per million habitants. Causes of
death differed between men, mainly due to neoplastic diseases,
and women, mainly due to primary graft failure and rejection
(18). All the described studies show a comparable pattern of
baseline characteristics and underlying heart disease.
Our study aims to describe sex-related differences in 1-year
outcomes after an HT in a contemporary cohort. Given that
previous studies showed sex-related differences in higher-risk
recipients, we sought to analyze 1-year HT results as they may
be affected considerably by perioperative factors like the patient’s
clinical situation on the waiting list or the etiology of HF.
We did not find differences in the recipient’s location
(outpatient or hospitalized) at the time of HT. The need for
circulatory support at the moment of HT was more frequent
in men (mainly VAD), but it was not associated with different
outcomes. VADs were used in a low percentage of HT candidates
in our cohort. Given that VAD therapy may have different
results in men and women, we cannot extrapolate our results to
other populations with a higher VAD use. Urgent HT was more
frequent in men, but it was not associated with higher mortality
after multivariate analysis. We cannot determine whether this
difference is influenced by a higher delisting rate of women due
to clinical deterioration before HT or different use of therapies
that determine urgent status in our country (i.e., intra-aortic
balloon pump until 2015, extracorporeal membrane oxygenator,
or VAD).
To conclude, despite sex-related differences in the clinical
profile and the donor-recipient matching, 1-year outcomes are
comparable. We did not find differences in the cause of death,
and we did not find any interactions between sex and factors
significantly associated with differences in survival.
LIMITATIONS
Our analysis of 1-year outcomes after HT has some limitations
that must be acknowledged. The main limitation is the lack of
information about patients included on the waiting list for HT
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since the patient’s follow-up begins at HT. Thus, we do not have
any data about those patients who are included on the waiting list
and are delisted or died before HT. Another limitation is the low
rate of VAD implantation in our cohort that prevents us from
extrapolating these results to other populations. Furthermore,
the retrospective nature of a registry analysis also constitutes a
significant limitation.
CONCLUSION
Women are under-represented in the waiting list for an HT
or a VAD. Although clinical profile and HF etiology differ
between men and women, overall survival and complications
are similar. It is desirable to study sex-related differences to
understand if we should adjust clinical protocols in advanced HF
patients by sex.
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